scholarly journals A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors

2019 ◽  
Author(s):  
Yan Ju ◽  
Lifeng Wang ◽  
Shengjun Ta ◽  
Rui Shu ◽  
Shanling Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Malignant Tumors ◽  
Chinese Han ◽  
Familial History ◽  
History Of ◽  
Germline Alteration

scholarly journals Intramammary Metastasis in a Patient with a History of Renal Cell Carcinoma: A Case Report

2018 ◽  
Vol 11 (2) ◽  
pp. 318-322
Author(s):  
Miyuki Kitahara ◽  
Yasuo Hozumi ◽  
Rio Asada ◽  
Aya Sawa ◽  
Hitoaki Saito ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Needle Biopsy ◽  
Malignant Tumors ◽  
Definitive Diagnosis ◽  
Benign Tumors ◽  
Immunohistochemical Examination ◽  
History Of

Intramammary metastasis of renal cell carcinoma (RCC) is extremely rare, accounting for only 1.5% of all intramammary metastases. Distinguishing intramammary metastases from benign tumors and breast cancer is clinically problematic. Some patients undergo excessive surgery after a misdiagnosis of breast cancer instead of a mammary tumor. We performed a core needle biopsy (CNB) of a breast mass that developed in a 71-year-old woman after surgeries for bilateral RCC and breast cancer, leading to a diagnosis of intramammary metastasis of RCC. In this case, the CNB and immunohistochemical examination were critical for reaching a definitive diagnosis. We conclude that, when examining patients with mammary tumors, establishing their history of malignant tumors may help diagnose intramammary metastasis and select the best treatment strategy.

Male breast cancer in patients with a familial history of breast cancer

Surgery Today ◽  
1996 ◽  
Vol 26 (12) ◽  
pp. 975-979 ◽  
Author(s):  
Sadako Akashi-Tanaka ◽  
Takashi Fukutomi ◽  
Atsuo Fukami ◽  
Takehiro Fujiki
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Familial History ◽  
History Of

Perceived risk and adherence to breast cancer screening guidelines among women with a familial history of breast cancer: A review of the literature

The Breast ◽  
2013 ◽  
Vol 22 (4) ◽  
pp. 395-404 ◽  
Author(s):  
Meghan J. Walker ◽  
Anna M. Chiarelli ◽  
Julia A. Knight ◽  
Lucia Mirea ◽  
Gord Glendon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Perceived Risk ◽  
Review Of The Literature ◽  
Familial History ◽  
Screening Guidelines ◽  
History Of

Nonhematologic neoplasia in biallelic BRCA2 mutated Fanconi anemia.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10041-10041
Author(s):  
Vasant Chinnabhandar ◽  
Todd E DeFor ◽  
Rebecca Tryon ◽  
John E Wagner ◽  
Margaret L MacMillan
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Solid Tumors ◽  
Fanconi Anemia ◽  
Malignant Tumors ◽  
Brca2 Mutation ◽  
Hematologic Malignancies ◽  
Cancer Surveillance ◽  
History Of ◽  
Brca2 Mutations

10041 Background: Fanconi anemia (FA) is a cancer predisposition disorder. Affected individuals do not tolerate conventional doses of chemotherapy or radiation well. Biallelic BRCA2 mutations cause a rare (̃3%) form of FA. Most patients with this subtype have a family history of breast cancer and die in early childhood. Optimal management remains uncertain. Herein, we report the world’s largest single center cohort of biallelic BRCA2 patients, with a focus on non-hematologic malignancies. Methods: The University of Minnesota’s prospectively maintained FA database was analyzed for data on biallelic BRCA2 mutated FA patients. IRB-approved consent was obtained for all subjects. Results: Twenty patients with biallelic BRCA2 were identified. Median age of FA diagnosis was 1.5 years (range: 0-16.2 years). All patients had a significant history of cancer in the family with breast cancer being particularly frequent (65%). Eight (40%) patients developed non-hematologic neoplasia before 18 years of age. These included 10 malignant tumors and 4 benign neoplastic lesions; 3 patients had more than one solid tumor (see Table). Surgical resection was attempted in all malignant tumors, dose reduced adjuvant chemotherapy was utilized in 5 cases and radiation in one case. Thirteen (65%) patients developed hematologic malignancies (AML=6, ALL=3, MDS=4), all without preceding marrow failure. Fourteen patients underwent allogeneic HCT. Eleven patients have died, 3 from solid tumors and 5 from leukemias. Nine patients are currently alive, of whom 3 are post-HCT. Only 4 (age range: 6.5-16.3 years) patients in the cohort remain free of any oncologic diagnoses. Conclusions: Patients with FA due to biallelic BRCA2 mutations have a unique phenotype with an extraordinarily high risk of early-onset de-novo acute leukemia and solid tumors, often both diagnosed in the same patient. They require extensive, lifelong cancer surveillance from an early age to optimize outcomes. Therapy for malignant diagnoses should aim to minimise exposure to genotoxic / crosslinking agents and radiation. BRCA2 mutation testing in family members and appropriate genetic counselling is essential. Additionally, a family history of BRCA2 mutated cancers should prompt FA testing in offspring with any relevant FA-related clinical findings. Nonhematologic neoplasia and therapy.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document